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Abstract
Background: Direct factor Xa (FXa) inhibitors are increasingly prescribed for outpa-
tients, and those transitioning to unfractionated heparin (UFH) for hospital admis-
sion are monitored via an anti-FXa assay. Because of assay interference, UFH results 
would often be critically elevated, confounding dosing.
Objectives: An anti-factor IIa (FIIa) UFH assay was evaluated for clinical use.
Methods: The BIOPHEN ANTI-IIa (Aniara Diagnostica) assay and anti-FXa 
INNOVANCE Heparin assay (Siemens Healthcare Diagnostics Products GmbH) 
were compared on the Siemens BCS XP system. Samples included UFH controls and 
calibrators and specimens from patients transitioning from apixaban or rivaroxaban 
to UFH. Method comparison, linearity, recovery, precision, and interference by di-
rect FXa inhibitors were evaluated. The effect of the BIOPHEN ANTI-IIa assay on 
the rate of critically high UFH results was retrospectively reviewed 4 months after 
implementation.
Results: Accuracy studies using 0.24 and 0.50 IU/mL UFH yielded means and stand-
ard deviations of 0.26 ± 0.01 and 0.58 ± 0.01 IU/mL, respectively. Within-run and 
between-run coefficients of variation were 4.6% and 15.5% for the low control, 
and 1.8% and 10.6% for the high control. The method comparison slope was 0.9965 
(r2 = 0.9468). The linear range was 0.1 to 1.3 IU/mL. The assay measured UFH in 
the presence of 192 ng/mL apixaban or 158 ng/mL rivaroxaban. Introduction of the 
assay for clinical use reduced the monthly percentage of critically high results from 
9.4% to 3.8% for admitted heparinized patients who recently discontinued apixaban 
or rivaroxaban.
Conclusions: The BIOPHEN ANTI-IIa assay is suitable for patients transitioning off 
apixaban or rivaroxaban.
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1  | INTRODUC TION
Oral direct factor Xa (FXa) inhibitors, such as rivaroxaban, apixaban, 
and edoxaban, are widely used in the management of venous throm-
boembolism and atrial fibrillation (AF).1 They selectively bind and 
inactivate the active sites of free and prothrombinase-complexed 
FXa, thereby decreasing thrombin generation. Direct FXa inhibitors 
are primarily excreted in urine and feces and exhibit terminal half-
lives of 5 to 15 hours, depending on the inhibitor.2 Because of these 
predictable pharmacokinetic properties, their use does not require 
drug level monitoring, belying their growing popularity. However, 
their presence in patient plasma specimens can cause interferences 
in numerous clinical coagulation assays, including prothrombin time 
coagulation factor assays, activated partial thromboplastin time co-
agulation factor assays, and lupus anticoagulant assays.3,4
Often, patients on direct FXa inhibitors are transitioned to 
shorter acting anticoagulants such as unfractionated heparin 
(UFH) when they are admitted to the hospital for invasive pro-
cedures or for new thrombosis. Within our health system, UFH 
levels in such patients are monitored via an anti-FXa assay with 
UFH calibrators. The risk of interference by direct FXa inhibi-
tors in this assay is high because their anti-FXa activities may be 
transformed into falsely increased UFH results.5 Indeed, Macedo 
et al. demonstrated the amount of critically high UFH results in 
inpatient units frequently transitioning patients from direct FXa 
inhibitors to UFH was higher than that of the overall hospital. 
Furthermore, such critically high results led to decreasing or even 
discontinuing UFH and triggered increased anti-FXa monitoring 
with negative implications on cost and patient convenience. They 
also opined that holding or reducing an UFH infusion because of 
an elevated anti-FXa level related to a direct FXa inhibitor may 
also pose undue harm to patients if this occurred in the context of 
an acute thrombotic event.5 Thus, a different management strat-
egy was necessitated.
The current study evaluates an assay for the quantitation of 
UFH based on the inhibition of thrombin (FIIa) rather than on FXa. 
The feasibility of adapting such an assay for a popular commercial 
automated clinical coagulation analyzer is demonstrated and its 
performance investigated with regard to linearity and recovery, 
measurement range, accuracy, precision, and interference by the 
direct FXa inhibitors on the University of Michigan pharmacy for-
mulary, rivaroxaban and apixaban. Via retrospective test utilization 
review, the effect of such an assay on the rate of critically high UFH 
in a selected population is quantified. Last, the implementation of 
the anti-FIIa UFH assay for a select patient population and alterna-
tives for a spectrum of clinical coagulation laboratory practices are 
discussed.
2  | METHODS
The BIOPHEN ANTI-IIa (2 Stages Heparin Assay) kit and UFH cali-
brators and controls were purchased from Aniara Diagnostica LLC. 
BIOPHEN apixaban and rivaroxaban calibrators and controls were 
also from Aniara Diagnostica. The purity of raw apixaban and rivar-
oxaban materials used in the creation of the calibrators and con-
trols were >99% per the manufacturer. The anti-FXa INNOVANCE 
Heparin Assay, UFH calibrators, and UFH controls were from 
Siemens Healthcare Diagnostics Products GmbH. CRYOcheck 
pooled normal plasma (NPP) was from Precision Biologic, Inc. UFH 
linearity samples were purchased from the College of American 
Pathologists. Fifty-four residual, posttest patient plasma specimens 
that were routinely submitted for anti-FXa UFH testing in blue-top 
BD Vacutainer tubes with 3.2% sodium citrate (Becton Dickinson 
and Company) were collected and deidentified for the study. The 
study met criteria for Not Regulated Human Research as set forth by 
the Institutional Review Board of the University of Michigan Medical 
School, Ann Arbor.
The INNOVANCE Heparin assay is cleared by the US Food 
and Drug Administration for clinical testing and was performed 
per manufacturer's instructions on the BCS XP system (Siemens 
Healthcare Diagnostics Products) without modification.6 Despite 
being designed for a Stago coagulation analyzer and manual test-
ing, the BIOPHEN ANTI-IIa kit was installed for use on a Siemens 
BCS XP system using the package insert and application guide to 
develop the assay program.7,8 The provided BIOPHEN ANTI-IIa 
assay synopsis was: sample diluted 1:40 in buffer, addition of R1 
(reagent containing human antithrombin), addition of R2 (reagent 
containing human thrombin) followed by a 120-second incubation 
at 37°C, addition of R3 (reagent containing a thrombin-specific 
chromogenic substrate), measuring the OD/min change in colori-
metric signal for 15 to 40 seconds at 405 nm, and calculating the 
UFH level using a Lin-Log calibration curve.7,8 To adapt this for 
the Siemens BCS XP system, incubation times and volumes were 
modified while keeping reagent and sample ratios constant. A Lin-
Lin calibration curve and a saline solution enzyme blank were also 
added. The programming was judged as successful when the cali-
bration curve was performed without any flags and the BIOPHEN 
UFH quality control values were within the manufacturer's de-
fined limits. The successful BCS XP system programming is sum-
marized in Figure S1. All anti-FIIa UFH levels for this study were 
Essentials
• Therapeutic direct factor Xa (FXa) inhibitors interfere 
with anti-FXa unfractionated heparin (UFH) assays.
• An UFH assay based on inhibition of thrombin (FIIa) was 
evaluated for clinical use.
• The anti-FIIa UFH assay was free from interference by 
direct FXa inhibitors, but also increased reagent costs.
• The anti-FIIa assay led to fewer critically high UFH re-
sults than the anti-FXa assay for patients transitioning a 
direct FXa inhibitor to UFH.
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measured using the BIOPHEN ANTI-IIa kit on the Siemens BCS 
XP system.
Method comparison between the anti-FXa INNOVANCE Heparin 
assay and the BIOPHEN ANTI-IIa assay was performed using a com-
bination of 16 UFH calibrator dilution samples, 2 UFH linearity sam-
ples, and 14 consecutive residual posttest samples from patients 
known to be anticoagulated only with UFH. Within-run precision 
of the BIOPHEN ANTI-IIa assay was performed by measuring the 
BIOPHEN UFH control levels 1 and 2 (0.24 and 0.50 IU/mL, respec-
tively9) 20 consecutive times. Between-run precision was performed 
by measuring the BIOPHEN UFH control materials one to six times 
per day for 25 days (n = 82). Linearity was performed by dilution of 
the INNOVANCE Heparin calibrators and BIOPHEN UFH controls 
into NPP and then measurement via the BIOPHEN ANTI-IIa assay. 
Recovery was assessed by dividing the measured linearity results by 
the expected UFH levels.
For in vitro interference studies, BIOPHEN apixaban and rivar-
oxaban Calibrator 2 (Cal2) and Control 2 (C2) were reconstituted 
per manufacturer's instructions by adding 1 mL NERL Reagent 
Grade Water (Thermo Fisher Scientific), shaking vigorously until 
complete dissolution, allowing to stabilize at room temperature 
for 30 minutes, and homogenizing before use. Per the Certificates 
of Analysis, reconstituted concentrations were 384 ng/mL for 
apixaban C2 (lot F1700657/F1700657), 290 ng/mL for apixaban 
Cal2 (lot F1700659/F1700660), 316 ng/mL for rivaroxaban C2 (lot 
F1600888), and 250 ng/mL for rivaroxaban Cal2 (lot F1700285/
F1700286). Although reconstituted controls are stable for 7 days 
at 2 to 8°C, vials prepared for the interference assays were used 
within 8 hours. The sensitivities of the INNOVANCE Heparin 
assay and the BIOPHEN ANTI-IIa assay to direct FXa inhibitors 
were evaluated with dilutions of apixaban and rivaroxaban Cal2 
in NPP in the absence of UFH. To test the assays’ ability to mea-
sure UFH in the presence of direct FXa inhibitors, samples with a 
range of UFH levels were assembled by mixing different amounts 
of BIOPHEN UFH Controls 1 and 2 with each other without di-
luent. Then, each of these UFH samples were combined 1:1 with 
equal volumes of reconstituted apixaban or rivaroxaban C2, and 
analyzed using the INNOVANCE Heparin assay and the BIOPHEN 
ANTI-IIa assay.
The stability of the BIOPHEN reagents including UFH controls 
was monitored hourly at room temperature for 24 hours without 
re-refrigeration. Calibration curve stability was indirectly monitored 
after BIOPHEN ANTI-IIa assay implementation by reviewing results 
of routine quality control testing.
The rate of critically high UFH results was retrospectively de-
termined. The inpatient units from which the BIOPHEN ANTI-IIa 
assay was most ordered were identified using the laboratory's 
information system, SCC Soft Computer SoftLab (Clearwater, FL) 
and results from the first 4 months of testing after implementation 
collected. From those same inpatient units, 4 months of results 
from the INNOVANCE Heparin assay immediately preceding im-
plementation of the BIOPHEN ANTI-IIa assay were also collected. 
From this preimplementation dataset, INNOVANCE Heparin assay 
results from patients transitioning onto UFH from apixaban or ri-
varoxaban were isolated via manual review using the Electronic 
Medical Record Search Engine available at the University of 
Michigan.10
Data were analyzed using GraphPad Prism 8.3.0. Statistical sig-




Forty-two samples free from direct FXa inhibitors (14 remnant 
patient specimens, 12 proficiency testing linearity samples, and 
16 UFH Calibrator dilutions) were tested using the INNOVANCE 
Heparin assay and BIOPHEN ANTI-IIa assay. Linear regression 
analysis of results from the two assays showed a slope of 0.9965 
(r2 = 0.9468) and a correlation coefficient, r, of 0.9730 (Figure 1A). 
F I G U R E  1   A, Method comparison between the INNOVANCE 
Heparin assay (“Anti-FXa UFH”) and the BIOPHEN ANTI-IIa 
assay (“Anti-FIIa UFH”) on 42 samples containing UFH as the 
only anticoagulant medication, including residual posttest patient 
specimens, commercial linearity samples, and UFH calibrator 
dilutions. The results were analyzed via linear regression (solid line, 
slope = 0.9965, r2 = 0.9468, solid line; dashed line, line of equality) 
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Relative bias was consistently within 20% by Bland-Altman anal-
ysis except when average results were below 0.1 IU/mL UFH 
(Figure 1B).
3.2 | Precision
The BIOPHEN UFH control level 1 has an expected UFH con-
centration of 0.24 IU/mL.9 Within-run precision showed a mean 
of 0.26 IU/mL, with a standard deviation (SD) of 0.01 IU/mL, and 
a coefficient of variation (CV) of 4.6%. Between-run precision 
showed a mean of 0.20 IU/mL, with a SD of 0.03 IU/mL, and a 
CV of 15.5%. The BIOPHEN UFH control level 2 has an expected 
UFH concentration of 0.50 IU/mL.9 Within-run precision showed a 
mean of 0.58 IU/mL, with an SD of 0.01 IU/mL, and a CV of 1.8%. 
Between-run precision showed a mean of 0.52 IU/mL, with an SD 
of 0.05 IU/mL, and a CV of 10.6%. Manufacturer-expected within-
run CVs for UFH control levels 1 and 2 were 6.6% and 4.1%,7 re-
spectively, whereas the maximally acceptable between-run CV is 
20% for University of Michigan Department of Pathology clinical 
laboratories.
3.3 | Linearity and recovery
Using INNOVANCE Heparin calibrator samples and BIOPHEN UFH 
control samples, 36 samples of known UFH concentration were 
created via dilution into NPP and analyzed by the BIOPHEN ANTI-
IIa assay. Linear regression analysis of measured anti-FIIa UFH re-
sults vs expected UFH concentration showed a slope of 0.9640 
(r2 = 0.9631; Figure 2A) with responses again becoming nonlinear 
below 0.1 IU/mL (Figure 2B). Recovery was 111 ± 20% across the 
concentrations tested. Based on the method comparison (Figure 1) 
and linearity results (Figure 2), the measurable UFH range for the 
BIOPHEN ANTI-IIa assay was set at 0.1 to 1.3 IU/mL.
3.4 | Interference
The sensitivities of the INNOVANCE Heparin assay and the BIOPHEN 
ANTI-IIa assay to direct FXa inhibitors were evaluated using doses 
of apixaban and rivaroxaban in NPP without UFH. The INNOVANCE 
Heparin assay reported the anti-FXa activities of the inhibitors as 
UFH levels across its reportable range (Figure 3A). However, the 
BIOPHEN ANTI-IIa assay was insensitive to apixaban and rivaroxa-
ban up to 400 ng/mL, reporting out no detectable UFH levels. To 
evaluate the performance of the assays in mixtures of UFH and di-
rect FXa inhibitor, a range of UFH concentrations were created by 
mixing BIOPHEN UFH control plasmas. Then, these were combined 
with apixaban (final concentration, 192 ng/mL) or rivaroxaban (final 
concentration, 158 mg/mL) and analyzed. The BIOPHEN ANTI-IIa 
assay yielded reportable results compatible with the expected UFH 
concentrations (Figure 3B). In contrast, by the INNOVANCE Heparin 
assay, all samples were resulted as >1.5 IU/mL, consistent with the 
interfering effect of apixaban and rivaroxaban in the anti-FXa UFH 
assay shown in Figure 3A.
3.5 | Assay stability
All BIOPHEN ANTI-IIa assay reagents were left on board the BCS 
XP system at room temperature, and the BIOPHEN UFH control 
levels 1 and 2 were run once every hour for 24 hours. For the first 
12 hours, the CVs were 5.6% and 16.5%, respectively (Figure 4). 
However, for the second 12 hours, the CVs worsened to 9.4% and 
24.6%, respectively (Figure 4), indicating reagent instability. To ad-
dress this problem, we implemented the procedure of storing all 
BIOPHEN ANTI-IIa reagents at 2 to 8°C, heating R1, R2, and R3 
to 37°C by placing on a heat block for 15 minutes just before use 
to ensure proper heat activation of the reagents, and analyzing the 
UFH control levels immediately before analyzing patient specimens. 
The BIOPHEN and INNOVANCE quality control aliquots are each 
used for up to 48 hours. The INNOVANCE controls are run once 
every 8 hours of patient testing or at each reagent vial change, while 
F I G U R E  2   To determine the linear range, manufacturers’ 
heparin control and calibrator materials were used to create 36 
samples of known UFH concentration which were then tested by 
the BIOPHEN ANTI-IIa assay. The results were analyzed by (A) 
linear regression (solid line, slope = 0.9640, r2 = 0.9631; dashed line, 











0.0 0.5 1.0 1.5
0.0 0.5 1.0 1.5
Expected UFH (IU/mL) 





















     |  1657STUART eT Al.
the BIOPHEN controls are run before every patient run. This belies 
the increased reagent cost per test of the BIOPHEN ANTI-IIa assay 
($3.83 USD) as compared to the INNOVANCE Heparin assay ($2.86 
USD).
The BIOPHEN ANTI-IIa assay calibration curve appears to be as 
stable as that for the INNOVANCE Heparin assay. In the year since 
it was implemented, the BIOPHEN ANTI-IIa assay was calibrated 
every 6 months as scheduled, once when there was an assay kit lot 
change and once when there was an unusual trend in quality control 
results. This was identical to anti-FXa INNOVANCE Heparin assay in 
the past year, which also required one recalibration from an unusual 
quality control result trend. Therefore, calibrator consumption is an-
ticipated to be comparable between the two assays.
3.6 | Effect on critically high results
The performance of the anti-FXa INNOVANCE Heparin assay and 
the BIOPHEN ANTI-IIa assay on specimens from patients tran-
sitioning from anticoagulation with direct FXa inhibitors to UFH 
were evaluated. Residual samples from 40 consecutive plasma 
specimens collected in the emergency department for routine UFH 
levels were tested by both assays. These specimens were from pa-
tients who were receiving outpatient treatment with apixaban or 
rivaroxaban, and were transitioned on UFH per anticoagulation 
guidelines for atrial fibrillation or acute coronary syndrome. In all 
cases, the INNOVANCE Heparin assay reported higher UFH re-
sults than the BIOPHEN ANTI-IIa assay (Figure 5). Furthermore, 
22 of the 40 samples were reported to have critically high UFH 
levels (>1.0 IU/mL) by the INNOVANCE Heparin assay, with 13 
of those results being above the reportable range (resulted as 
>1.5 IU/mL but plotted as 1.5 IU/mL). In contrast, by the BIOPHEN 
F I G U R E  3   A, Samples of apixaban (closed triangles) or 
rivaroxaban (open circles) in NPP without UFH were tested with 
the INNOVANCE Heparin assay (“Measured Anti-FXa UFH”) in 
triplicate. The BIOPHEN ANTI-IIa assay reported no detectable 
UFH levels for up to 400 ng/mL apixaban or rivaroxaban because 
all samples were resulted as below the assay's reportable range. 
B, A range of UFH concentrations with either 192 ng/mL apixaban 
(closed triangles) or 158 ng/mL rivaroxaban (open circles) were tested 
by the BIOPHEN ANTI-IIa assay (“Measured Anti-FIIa UFH”). When 
the same samples were tested using the INNOVANCE Heparin 
assay, all results were > 1.5 IU/mL, exceeding the reportable UFH 
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B F I G U R E  4   The stability of the BIOPHEN reagents and controls 
were evaluated by leaving them on board the BCS XP system 
at room temperature. Once per hour for 24 hours, UFH control 
levels 1 (open circles) and 2 (closed triangles) were tested using the 
BIOPHEN ANTI-IIa assay. The CV was calculated for each level of 
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ANTI-IIa assay, no results were above the reportable range, and 
only 2 of the 40 samples were reported to have critically high 
UFH levels. These two high anti-FIIa UFH results appeared to be 
truly the result of supratherapeutic plasma UFH concentrations 
because contemporaneous activated partial thromboplastin times 
results were also critically prolonged beyond the reportable range 
(>120 seconds) for both patients and neither had been given other 
potentially interfering anticoagulants such as argatroban, dabi-
gatran, or enoxaparin.
The effect of the BIOPHEN ANTI-IIa assay on critically high 
UFH results was retrospectively studied as described for patients 
transitioning from direct FXa inhibitors to UFH. Approximately 75% 
of BIOPHEN ANTI-IIa assay orders were from six inpatient clinical 
areas: four cardiology units, one medical acute care unit, and one 
medical/surgical moderate care unit. The UFH results from patients 
in these units were analyzed for 4 months immediately before and 
immediately following implementation of the BIOPHEN ANTI-IIa 
assay for clinical use. Common indications for outpatient use of 
apixaban or rivaroxaban included AF and history of deep venous 
thrombosis and/or pulmonary embolism. Common indications for in-
patient transition to UFH included ACS, cardioversion, and coronary 
artery catheterization, as well as unrelated comorbidities and proce-
dures/surgeries. Preimplementation, only the anti-FXa INNOVANCE 
Heparin assay was available to monitor UFH and yielded a monthly 
percentage of critically high results of 9.4% (6.2%-14.2%) (median, 
25th-75th percentile) (Figure 6). Postimplementation, patients with 
recent apixaban or rivaroxaban use were first monitored via the 
BIOPHEN ANTI-IIa assay and then the INNOVANCE Heparin assay, 
yielding a significantly decreased percentage of critically high results 
at 3.8% (3.4%-4.9%) (n = 4, P = 0.0286). The percentage of critically 
high UFH results from the BIOPHEN ANTI-IIa assay alone was even 
lower at 1.3% (0.3%-2.9%) (P = 0.0286, compared with preimple-
mentation percentages). These findings imply that the BIOPHEN 
ANTI-IIa assay can prevent falsely high UFH results in real-world 
clinical settings.
4  | DISCUSSION
The inability to appropriately adjust UFH dosing in patients transi-
tioning from direct FXa inhibitors to UFH compromises the therapeu-
tic efficacy of UFH, the safety of patients, and the ability of hospitals 
to provide high quality patient care. Our approach to addressing this 
problem involves a close collaboration between the Departments of 
Pathology and Pharmacy. It was agreed that the solution should be 
straightforward for the laboratory and compatible with the existing 
dosing nomogram based on peripheral blood UFH levels. Validation 
of an anti-FIIa UFH assay as a laboratory derived test met those 
criteria. To avoid overutilization because of its increased cost and 
slightly more complex workflow, the BIOPHEN ANTI-IIa assay is a 
restricted test. Pharmacy colleagues remain instrumental in identi-
fying appropriate patients for the BIOPHEN ANTI-IIa assay as well as 
in determining the appropriate time at which a patient's UFH levels 
can be safely monitored by the anti-FXa INNOVANCE Heparin assay 
after clearance of any direct FXa inhibitors. We now also leverage 
the electronic medical record to alert providers ordering the UFH 
F I G U R E  5   Specimens from 40 patients on a direct FXa inhibitor 
who presented to the ED and were subsequently started on UFH 
per institutional atrial fibrillation or acute coronary syndrome 
anticoagulation guidelines were tested using the INNOVANCE 
Heparin assay (“Anti-FXa") and the BIOPHEN ANTI-IIa assay (“Anti-



















F I G U R E  6   The monthly percentage of critically high UFH 
results for inpatient units frequently using the BIOPHEN ANTI-IIa 
assay for patients transitioning from a direct FXa inhibitor to UFH 
was analyzed for 4 months before and after implementation of the 
assay for clinical use. Preimplementation UFH results were from 
the INNOVANCE Heparin assay only, whereas postimplementation 
UFH results were from a combination of the INNOVANCE Heparin 
assay and the BIOPHEN ANTI-IIa assay. The rates of critically 
high UFH results from the BIOPHEN ANTI-IIa assay (“Anti-FIIa 
UFH only”) were also examined. Significance was analyzed using a 
nonparametric, two-tailed Mann-Whitney U test (*P < 0.05). Lines 
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nomogram whether their patients have recent direct FXa inhibitor 
use and to direct providers to the appropriate laboratory testing and 
UFH monitoring strategy.
There are alternative laboratory solutions that avoid interfer-
ence in UFH monitoring by direct FXa inhibitors. Before testing, pa-
tient plasma specimens can be pretreated with activated charcoal 
products, DOAC-Stop (Australian Scientific Enterprise, Hornsby, 
NSW)11 or DOAC-Remove (5-Diagnostics AG, Basel, Switzerland), 
which can remove several classes of direct oral anticoagulants. 
DOAC-Stop is reported to completely remove 1000 ng/mL apix-
aban or 600 ng/mL rivaroxaban in NPP, whereas in separate 
samples, having no effect on 200 ng/mL UFH or 4000 ng/mL enox-
aparin.11 However, pretreatment with activated charcoal would 
have added an additional manual step to the laboratory workflow 
and would contribute to additional cost added to the assay itself. 
Thrombin time was also considered because it is also not affected 
by direct FXa inhibitors. However, this would have required the 
creation and validation of an entirely new UFH dosing nomogram 
based on thrombin time, as well as training of clinical staff to use 
the new nomogram in addition to the pre-existing one based on 
measured UFH level. Although these alternatives did not meet the 
needs of our laboratory users, they may be more appropriate op-
tions than the BIOPHEN ANTI-IIa assay for other institutions after 
workflow, cost, and clinical experiences are weighed.
There are important limitations to the BIOPHEN ANTI-IIa 
assay. First, although it is insensitive to direct FXa inhibitors, based 
on its methodology, the assay is likely susceptible to interference 
by other anticoagulants, such as enoxaparin, fondaparinux, and 
dabigatran. Such analytical error is best mitigated via acquisition 
of accurate medication histories and judicious use of the assay 
only for patients treated with direct FXa inhibitors and initi-
ating UFH therapy. In cases where clinical information may be 
unavailable, such as in unresponsive patients, we would use the 
anti-FXa INNOVANCE Heparin assay having no indication to use 
the BIOPHEN ANTI-IIa assay. If anti-FXa UFH levels are unex-
pectedly high, we would correlate with activated partial throm-
boplastin time and anti-FIIa UFH results, as well as continue 
efforts to gather relevant clinical history. Second, the addition of 
exogenous human antithrombin may cause the BIOPHEN ANTI-
IIa assay to overestimate the biological effect of UFH in patients 
with antithrombin deficiency and lead to subtherapeutic antico-
agulation. Although the frequency of hereditary antithrombin 
deficiency is about 1 in 2000 to 3000 individuals, acquired an-
tithrombin deficiency is associated with liver disease, malnutri-
tion, nephrotic syndrome, hemodialysis, sepsis, and major surgery 
and trauma.12 Anti-FXa INNOVANCE Heparin assay results that 
are incongruently low compared with UFH dosing may indicate 
the presence of underlying antithrombin deficiency; however, 
in the presence of direct FXa inhibitors, that scenario would be 
unlikely. Therefore, neither assay is ideal for antithrombin-defi-
cient patients with both direct FXa inhibitors and UFH in their 
circulation. In our clinical practice, we aim to promptly discon-
tinue use of the BIOPHEN ANTI-IIa assay and convert patients 
to the INNOVANCE Heparin assay after the expected clearance 
of direct FXa inhibitors, which would somewhat mitigate assay 
inflation of the biological UFH effect. If antithrombin deficiency 
is suspected and needs to be ruled out but direct FXa inhibitor 
effect is still present, FIIa-based antithrombin activity assays or 
immunologic antigen assays would be preferred over FXa-based 
activity assays.
There were also limitations to this study. First, the validation 
relied on spiked UFH samples to supplement residual patient 
specimens to interrogate the entire clinically relevant range of the 
UFH assays. Deidentified posttest residual patient samples gener-
ally provided UFH levels in the low end of the therapeutic range. 
Purchased UFH linearity samples and reagent plasma spiked with 
UFH calibrator dilutions were required to evaluate the assays in 
the high end of the therapeutic range and the supratherapeutic 
range. Consequently, UFH sources and specimen matrices were 
nonidentical. Interference experiments were also subject to a 
similar limitation. UFH and direct FXa inhibitor levels cannot be 
determined in residual specimens from patients on both types 
of anticoagulant resulting from mutual assay interference. Thus, 
samples with known amounts of UFH and apixaban or rivaroxaban 
had to be created in the laboratory to assess the performance of 
the BIOPHEN ANTI-IIa and INNOVANCE Heparin assays in the 
presence of direct FXa inhibitors. A second limitation was that all 
patient specimens used for this validation study were from adults 
because anti-FIIa assays are reported to be less responsive than 
anti-FXa assays to UFH in pediatric patients.13 Therefore, the val-
idated BIOPHEN ANTI-IIa assay is only available for adult patients 
at University of Michigan.
As direct FXa inhibitors continue to gain popularity, current 
approaches to patient UFH monitoring will need to be adjusted or 
augmented to reduce interference and delay to reaching appropri-
ate dosing of UFH. Here we have shown that for a targeted patient 
population, a test method based on the anti-FIIa activity of UFH is 
a viable solution. The BIOPHEN ANTI-IIa assay is able to provide 
actionable UFH results in the presence of direct FXa inhibitors and 
should be considered for addition to the anticoagulation manage-
ment toolbox of clinical coagulation laboratories.
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